SCHEMBL10185361

SCHEMBL10185361

Cc1cc(O[C@H]2CC[C@@H](C(=O)O)CC2)ccc1C(=O)NCCNC(=O)c1cccc(C2CC2)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC5A7 Q9GZV3 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CCR3 P51677 1/20 0.41
ACSL1 P33121 7/20 0.40
S1PR5 Q9H228 1/20 0.40
DHODH Q02127 1/20 0.40
DRD2 P14416 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
DGAT1 O75907 2/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10184366 0.91 PDE4A (0.41) ACSL1S1PR5PDE4APDE4BPDE4C
SCHEMBL10185023 0.89 DGAT1 (0.46) SLC5A7NPC1RAB9AMEN1KMT2A
SCHEMBL10186163 0.89 HRH3 (0.41) SLC5A7NPC1RAB9AMEN1KMT2A
SCHEMBL10186172 0.88 CHRM1 (0.47) SLC5A7NPC1RAB9AMEN1KMT2A
SCHEMBL10184386 0.86 CCR3 (0.42) SLC5A7NPC1RAB9AMEN1KMT2A
SCHEMBL10185356 0.86 HRH3 (0.42) ACSL1S1PR5DHODHPDE4APDE4B
SCHEMBL10184943 0.86 DGAT1 (0.46) SLC5A7RAB9AACSL1DRD2DGAT1
SCHEMBL10185364 0.84 CCR3 (0.44) SLC5A7NPC1RAB9AMEN1KMT2A
SCHEMBL10186162 0.84 CCR3 (0.44) CCR3ACSL1DGAT1ALDH1A1
SCHEMBL10185105 0.84 CCR3 (0.49) NPC1RAB9ACCR3ACSL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
WO-2010122968-A1 DIACYLETHYLENEDIAMINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 SLC5A7 333/4885NPC1 201/4885RAB9A 1660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.